George P. Kim, MD | Authors


Regorafenib in the Treatment of Colorectal Cancer

September 16, 2013

Regorafenib is a recently approved oral, multikinase inhibitor for refractory colorectal cancer. Although structurally similar to sorafenib, it more potently inhibits a broader spectrum of critical growth receptor pathways, including those regulating angiogenesis and aberrant cellular proliferation.